Alverine

Source: Wikipedia, the free encyclopedia.
Not to be confused with Alvameline.
Alverine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
  • UK:
    General sales list
    (GSL, OTC)
Identifiers
  • N-Ethyl-3-phenyl-N-(3-phenylpropyl)propan-1-amine
JSmol)
  • c1ccccc1CCCN(CC)CCCc2ccccc2
  • InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3 checkY
  • Key:ZPFXAOWNKLFJDN-UHFFFAOYSA-N checkY
  (verify)

Alverine is a drug used for

gut and uterus
.

Adverse effects

The side effects of alverine include:[1][2]

  • Difficulties in breathing or shortness of breath, wheezing, swelling of the face or other parts of the body (associated with serious
    allergic reaction
    )
  • Yellowing of the whites of the eyes and the skin, due to liver inflammation
  • A feeling of nausea or dizziness
  • Headache
  • Minor allergic reaction (skin rash/itching)

It was reported that alverine may induce toxic hepatitis.[3][4]

Mechanism of action

Alverine acts directly on the muscle in the gut, causing it to relax. Alverine is a 5HT1A antagonist, which reduces rectal hypersensitivity.

diarrhoea. By relaxing the gut muscle, alverine citrate relieves the symptoms of this condition. Alverine also relaxes the smooth muscle in the womb (uterus). It is therefore also used to treat painful menstruation, which is caused by muscle spasms in the uterus (dysmenorrhea
).

Alverine capsules[7] are now available in the market. There are two strengths of capsule - 60 mg and 120 mg. The common dosage for adults and children over 12 years is 60–120 mg taken one, two or three a day, either before or after meals. Alverine is not suitable for those aged under 12 years. Women who are pregnant or breast-feeding should follow the instruction of doctors for the drug.

Development and marketing

A combination of alverine citrate and simeticone (ACS) for irritable bowel syndrome therapy were compared with placebo in a phase IV clinical trial.[8] At week 4, the alverine citrate and simeticone group had lower VAS scores for abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with the placebo group.[9]

The drug was firstly authorized for marketing on 03/06/2014. The marketing authorisation holder is Dr. Reddy's Laboratories (UK) Ltd.[10]

References

  1. ^ "Alverine capsules - Spasmonal, Audmonal. Side effects; dosage | Patient". Patient. Retrieved 2015-12-06.
  2. ^ "Alverine Citrate Patient Information Leaflet" (PDF). Medicines.org.uk. 2014. Archived from the original (PDF) on 2017-12-01.
  3. PMID 16378311. Archived from the original
    (PDF) on 2018-11-23.
  4. PMID 15259090
    .
  5. PMID 11697552
    .
  6. ^ "Detailed Info About Irritable bowel syndrome". Retrieved 2017-07-26.
  7. ^ "Alverine Citrate 60 mg Hard Capsules". Drugs.com. Retrieved 2015-12-06.
  8. ^ Clinical trial number NCT00542295 for "Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome" at ClinicalTrials.gov
  9. S2CID 35881469
    .
  10. ^ "Alverine citrate 60 mg hard capsules - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Retrieved 2015-12-06.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Alverine&oldid=1212694410"